Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy

Background: Current treatment guidelines for arrhythmogenic right ventricular cardiomyopathy (ARVC) mainly emphasize on prevention of ventricular arrhythmic events. Despite the progressive nature of ARVC, therapeutic options focusing on decelerating disease progression are scarce. Methods and Result...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Bin, Wu, Lingmin, Zheng, Lihui, Liu, Shangyu, Sheng, Lishui, Liu, Limin, Zhu, Zhenghui, Yao, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632763/
https://www.ncbi.nlm.nih.gov/pubmed/34869685
http://dx.doi.org/10.3389/fcvm.2021.769138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632763/
https://www.ncbi.nlm.nih.gov/pubmed/34869685
http://dx.doi.org/10.3389/fcvm.2021.769138

Ejemplares similares